Merus
Labs International Inc. (MSLI) is a pharmaceutical company that
focuses on acquiring, licensing, and marketing prescription drugs
primarily in North America. The company is headquartered in Toronto,
Canada and was founded in 2011.
Merus Labs acquires and markets
drugs in a variety of therapeutic areas including men's health,
urology, and cardiovascular diseases. Its products include Estrace
cream, a product used for treating vulvar and vaginal atrophy in
postmenopausal women; ELIGARD, a drug used for treating advanced
prostate cancer; and Vancocin, a drug used for treating severe C.
difficile-associated diarrhea. The company also provides drugs used in
hospitals for treating various diseases and conditions.
In
recent years, Merus Labs has made several acquisitions in order to
expand its portfolio of products. In 2015, the company acquired a
portfolio of products from ANIP Acquisition Company. In 2016, Merus
Labs acquired a portfolio of established products from Novartis AG.
Merus Labs is listed on the Toronto Stock Exchange under the
ticker symbol MSLI. In 2017, the company was acquired by Norgine B.V.,
a European pharmaceutical company, for approximately CAD 3
|
